onc Videos

Videos

Conference Coverage

Optimizing Treatment Methods Among Patients With Newly Diagnosed AML

10/17/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Justin Kaner, MD, discusses various treatment methods that optimize management of patients with newly diagnosed acute myeloid leukemia, including transplant evaluations and timeliness of test...

At the 2024 Lymphoma, Leukemia &...

10/17/2024

Oncology

Alberto Montero, MD, UH Seidman Cancer Center

Videos

STX-478 Demonstrates Promise in Heavily Pre-Treated Patients With PI3Kα-Mutated Solid Tumors

10/17/2024

Alberto Montero , MD;

Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.

Alberto Montero, MD, discusses...

10/17/2024

Oncology

Federico Cappuzzo, MD, National Cancer Institute Regina Elena

Videos

The Impact of Subcutaneous Formulation of Atezolizumab on Treatment for Patients with Non-Small Cell Lung Cancer

10/17/2024

Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.

Federico Cappuzzo, MD, discusses...

10/17/2024

Oncology

Conference Coverage

Exploring Diagnostic Criteria and Treatment Options for Patients With CMML

10/17/2024

At the 2024 Lymphoma, Leukemia & Myeloma Congress, Mrinal Patnaik, MD, discusses strategies for diagnosing and treating patients with chronic myelomonocytic leukemia.

At the 2024 Lymphoma, Leukemia &...

10/17/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Targeted DNA Sequencing for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL

10/15/2024

Erin Wiedmeier-Nutor, MD, discusses study results that compare a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations with a fluorescence in situ hybridization panel among untreated patients...

Erin Wiedmeier-Nutor, MD,...

10/15/2024

Oncology

Videos

Best Management Practices for a Patient With Early-Stage Non-Small Cell Lung Cancer

10/10/2024

Koosha Paydary, MD, Rush MD Anderson Cancer Center, discusses the course of treatment he would take for a patient with early-stage non-small cell lung cancer.

Koosha Paydary, MD, Rush MD...

10/10/2024

Oncology

Videos

Antibody-Drug Conjugates for Endometrial Cancer

10/10/2024

Mariana Gouveia, MD, gives an overview of the use of antibody-drug conjugates for the treatment of patients with endometrial cancer.

Mariana Gouveia, MD, gives an...

10/10/2024

Oncology

Abigail Zamorano, MD, MPHS, UT Health Houston

Videos

Using the PREMM5 Model for Lynch Syndrome Screening in Colorectal or Endometrial Cancer

10/08/2024

Abigail Zamorano, MD, MPHS, shares insights from a pilot study assessing a clinical algorithm, the the PREMM5 model, to evaluate a patient’s risk of carrying a Lynch Syndrome mutation, particularly in low-resource settings.

Abigail Zamorano, MD, MPHS,...

10/08/2024

Oncology

Conference Coverage

Analyzing Management and Treatment Options for Patients With High-Risk MDS

10/08/2024

Guillermo Garcia-Manero , MD;

At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.

At the 2024 SOHO meeting,...

10/08/2024

Oncology

Videos

Tarlatamab Plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung Cancer

10/08/2024

Sally Lau , MD;

Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.

Sally Lau, MD, discusses results...

10/08/2024

Oncology

Recent News

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology

News

Extended Lymphadenectomy Fails to Improve Survival Outcomes for Patients With Muscle-Invasive Bladder Cancer

11/05/2024

Stephanie Holland ;

Results from the phase 2 SWOG S1011 study demonstrated that extended lymphadenectomy failed to improve survival compared to standard lymphadenectomy among patients with localized muscle-invasive bladder cancer.

Results from the phase 2 SWOG...

11/05/2024

Oncology

News

Tumor Molecular Features Contribute Substantially to Overall Survival Disparities Among Patients With Colorectal Cancer

11/05/2024

Allison Casey ;

According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.

According to a single-center...

11/05/2024

Oncology

News

First-Line Durvalumab Plus Platinum-Doublet Chemotherapy Prolongs Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/04/2024

Stephanie Holland ;

According to results from a real-world comparison study, first-line durvalumab plus platinum-doublet chemotherapy prolonged survival compared to first-line atezolizumab plus platinum-doublet chemotherapy for patients with extensive-stage...

According to results from a...

11/04/2024

Oncology

News

Gilteritinib Following AlloHCT Shows No Improvement in Health-Related Quality of Life Among Patients With FLT3-ITD AML

10/31/2024

Gilteritinib maintenance therapy following allogeneic hematopoietic cell transplantation among patients with FLT3-ITD acute myeloid leukemia was not associated with any difference in health-related quality of life when compared with a...

Gilteritinib maintenance therapy...

10/31/2024

Oncology

News

Safety of Encorafenib Plus Binimetinib and Pembrolizumab for Advanced BRAF V600-Mutant Melanoma

10/31/2024

A safety lead-in for the STARBOARD trial found that both doses of encorafenib under evaluation, in combination with binimetinib and pembrolizumab, demonstrated safety that was comparable to the known profile for each agent.

A safety lead-in for the...

10/31/2024

Oncology

News

Novel Next-Generation Sequencing Assay Proves Accurate in Detecting Mutations Among Patients Advanced HR-Positive, HER2-Negative Breast Cancer

10/31/2024

A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.

A multi-gene target panel NGS...

10/31/2024

Oncology